Literature DB >> 19786972

A case of neuro-Behcet's disease presenting with lumbar spinal cord involvement.

B Zhao1, L He, X-H Lai.   

Abstract

STUDY
DESIGN: Case report.
OBJECTIVES: To report an unusual case of neuro-Behcet's disease (NBD) presenting with isolated myelitis that affected the lumbar cord.
SETTING: Department of Neurology, West China Hospital, Chengdu, Sichuan, China.
METHODS: A 19-year-old man presented with a 3-day history of paresthesia and weakness in both the legs. He had a 6-year history of recurrent oral and genital ulcers with erythema nodosum on his legs. Magnetic resonance imaging (MRI) revealed a T1-hypointense and T2-hyperintense lesion at the L1 level. Nodular enhancement of the lesion was achieved with gadolinium administration. Biopsy specimens from cutaneous lesions were consistent with an active perivasculitic process.
RESULTS: Corticosteroid (pulsed methylprednisolone followed by oral prednisolone) therapy was administered immediately. Subsequently, the patient's clinical condition improved dramatically. The spinal cord lesion disappeared on the MRI performed 1 year later. Thus far, there has been no recurrence.
CONCLUSION: NBD may involve the lumbar spinal cord. Prompt recognition of this disease and early vigorous steroid therapy are important to prevent further disability and recurrence.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19786972     DOI: 10.1038/sc.2009.124

Source DB:  PubMed          Journal:  Spinal Cord        ISSN: 1362-4393            Impact factor:   2.772


  2 in total

1.  Behcet's disease presenting with sudden-onset paraplegia due to anterior spinal artery involvement: 1-year follow-up of rehabilitation in conjunction with medication.

Authors:  Iltekin Duman; Umut Guzelkucuk; Kutay Tezel; Koray Aydemir; Bilge Yılmaz
Journal:  Rheumatol Int       Date:  2011-12-23       Impact factor: 2.631

Review 2.  Transverse myelitis.

Authors:  Shin C Beh; Benjamin M Greenberg; Teresa Frohman; Elliot M Frohman
Journal:  Neurol Clin       Date:  2013-02       Impact factor: 3.806

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.